Shichun Lu

5PUBLICATIONS
8CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 06, 2026
Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial.

|Dec 16, 2025
Contrast-enhanced US Evaluation of Residual Hepatocellular Carcinoma Following Lenvatinib Combined with Anti-PD-1 Antibody Downstaging Therapy.

Lianhua Zhu, Bo Jiang, Xiang Fei

|Oct 01, 2025
NQO1/p65/CXCL12 Axis-Recruited Tregs Mediate Resistance to Anti-PD-1 Plus Lenvatinib Therapy in PIVKA-II-Positive Hepatocellular Carcinoma.

Biao Gao, Yafei Wang, Zhuoya Sun

|Aug 09, 2024
Prediction Model for Immunotherapy Efficacy in Hepatocellular Carcinoma Based on Alternative Splicing Sequencing Data.

Huizhong Shi, Yang Liu, Zhao Liu

|Sep 20, 2023
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.

Wenwen Zhang, Shuang Tong, Bingyang Hu

Pageof 1

Frequent Collaborators

1 joint publications

Ze Zhang

1 joint publications

Lianhua Zhu

1 joint publications

Bo Jiang

1 joint publications

Xiang Fei